Harlequin Ichthyosis: From Near-Universal Infant Mortality to a Managed Chronic Disease

A newborn with harlequin ichthyosis is encased in rigid, armor-like skin that cannot flex, breathe, or protect. The thick hyperkeratotic plates covering the body restrict chest movement, making breathing difficult. Deep fissures between the plates breach the skin barrier, allowing fluid to escape and pathogens to enter. Eyelids are pulled back and lips everted. Until recent decades, virtually no affected infant survived beyond the first weeks of life.

That clinical picture has changed substantially. A comprehensive review published in the Journal of Exploratory Research in Pharmacology in February 2026 examines how the condition has evolved from an almost universally fatal neonatal emergency into a severe but manageable chronic disease - and where future therapies may take it.

The Molecular Root: ABCA12 and Lipid Transport Failure

Harlequin ichthyosis results from loss-of-function mutations in ABCA12, a gene encoding a lipid transporter found in keratinocyte lamellar granules. In normally functioning skin cells, ABCA12 transports glucosylceramide - a lipid molecule - to the surface of the outermost skin layer, where it forms part of the critical barrier that prevents water loss and blocks pathogen entry.

When ABCA12 fails, that transport process collapses. The stratum corneum lipid barrier cannot form properly. Keratinocytes respond to the compromised barrier with compensatory hyperproliferation, generating far more keratin than normal. The result is the massive keratin accumulation that produces the characteristic rigid plates, along with the retention of corneocytes that would normally be shed as part of routine skin renewal.

The condition is inherited as an autosomal recessive trait. Parents who each carry one mutated copy of ABCA12 face a 25 percent chance of having an affected child with each pregnancy. Incidence is estimated at roughly 1 in 300,000 births globally.

Survival Has Improved - but the Neonatal Period Remains Critical

Neonatal intensive care has been the most important factor in improved survival. The immediate challenges are fluid balance, infection prevention, respiratory support, and feeding difficulties. Without skilled intensive care, these cascading complications are rapidly lethal.

Systemic retinoids - primarily oral acitretin - represent the closest thing to disease-modifying therapy currently available. Initiated early, they accelerate the shedding of hyperkeratotic scale and improve skin pliability. Daily emollient application and keratolytics remain essential maintenance. Ophthalmologic care for ectropion, physical therapy for joint contractures, and psychosocial support round out the multidisciplinary management approach.

Long-term retinoid use carries its own monitoring requirements: hepatotoxicity and skeletal effects from prolonged treatment need regular surveillance. The therapy manages the condition rather than correcting its cause.

Emerging Approaches: Gene Therapy and CRISPR

Gene therapy and CRISPR-Cas9 approaches targeting ABCA12 correction in patient-derived cells are under investigation, though they remain early in development. The review highlights two parallel tracks: direct gene correction in keratinocytes, and stem cell-based strategies using gene-corrected induced pluripotent stem cells to generate autologous skin equivalents for grafting.

Neither approach has reached clinical trials for harlequin ichthyosis specifically. Delivering gene therapy to all affected keratinocytes across the entire body surface is technically far more complex than targeting a single organ, and the immune system may respond to delivery vectors or corrected cells. Nanotechnology-based topical delivery systems and pharmacological agents targeting alternative lipid pathways are being explored as additional routes.

The review notes that international registries and standardized outcome measures are urgently needed to enable adequately powered clinical trials for a disease affecting so few patients globally.

Living with Harlequin Ichthyosis

Survival into adulthood is now achievable with aggressive, sustained care. Adults with the condition face persistent hyperkeratosis, ongoing skin care demands, ocular issues, and significant psychosocial challenges. Quality of life varies considerably and depends substantially on access to specialized dermatologic and multidisciplinary care - access that is unevenly distributed globally.

The trajectory of the condition over the past three decades illustrates a pattern common in rare genetic skin diseases: improved understanding of the molecular mechanism, combined with advances in neonatal intensive care, has shifted the prognosis from uniformly fatal to variable and manageable. The next shift - toward therapies that address the underlying genetic defect - is the research community's current objective.